Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03425331

Recruitment Status : Suspended (Slow accrual, competing studies, and lack of efficacy)

First Posted : February 7, 2018

Last Update Posted : April 25, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Mark Awad, MD, Dana-Farber Cancer Institute

Results Submitted - Quality Control (QC) Review Has Not Concluded

Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status :	Suspended
Actual Primary Completion Date :	May 18, 2020
Estimated Study Completion Date :	August 28, 2025

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	December 20, 2023	January 17, 2024 Submission with QC Comments
2	February 7, 2024	March 6, 2024 Submission with QC Comments
3	April 30, 2024

To Top